vadimezan has been researched along with Experimental Mammary Neoplasms in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Busk, M; Horsman, MR; Iversen, AB | 1 |
| Chen, G; Horsman, MR; Pang, Q; Pedersen, M; Stødkilde-Jørgensen, H | 1 |
| Lee, AE; McKeage, MJ; Pruijn, FB; Shalal-Zwain, S; Siim, BG; Wilson, WR | 1 |
| Horsman, MR; Murata, R | 1 |
| Baguley, BC; Ching, LM; Goldthorpe, M; Kirker, JA; Liu, JJ; McKeage, MJ; Sutherland, R | 1 |
| Baguley, BC; Cliffe, S; Hill, RP; Rutland, M; Taylor, ML; Wilson, WR | 1 |
| Denny, WA; Lee, HH; Li, AE; Patterson, LH; Pullen, SM; Thompson, KM; Wilson, WR | 1 |
| Holford, NH; Pruijn, FB; van Daalen, M; Wilson, WR | 1 |
| Laux, WT; Palmer, BN; Rutland, MD; Siim, BG; Wilson, WR | 1 |
| Horsman, MR; Murata, R; Overgaard, J; Siemann, DW | 1 |
| Baguley, BC; Thomsen, LL; Wilson, WR | 1 |
11 other study(ies) available for vadimezan and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy.
Topics: Animals; Antineoplastic Agents; Blood Vessels; Chemoradiotherapy; Diphosphates; Female; Flavonoids; Hypoxia; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Oxygen; Stilbenes; X-Ray Therapy; Xanthones | 2013 |
The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours.
Topics: Animals; Antineoplastic Agents; Body Water; Diffusion; Female; Magnetic Resonance Imaging; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Regional Blood Flow; Stilbenes; Time Factors; Xanthones | 2008 |
Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Carboplatin; Dose-Response Relationship, Drug; Drug Synergism; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Paclitaxel; Stilbenes; Time Factors; Xanthenes; Xanthones | 2003 |
Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Female; Hyperthermia, Induced; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Inbred Strains; Neoplasm Transplantation; Skin; Temperature; Xanthones | 2004 |
Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinogens; Cytokines; Female; Immunoassay; In Situ Nick-End Labeling; Mammary Neoplasms, Experimental; Methylnitrosourea; Rats; Xanthones | 2007 |
Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid.
Topics: Aniline Mustard; Animals; Antineoplastic Agents; Drug Synergism; Female; Flavonoids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Regional Blood Flow; Tirapazamine; Triazines; Xanthenes; Xanthones | 1994 |
Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.
Topics: Acridines; Animals; Anthraquinones; Antineoplastic Agents; Cell Survival; Humans; Intercalating Agents; Mammary Neoplasms, Experimental; Mice; Nitracrine; Oxidation-Reduction; Prodrugs; Xanthenes; Xanthones | 1996 |
Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Hypoxia; Drug Synergism; Female; Mammary Neoplasms, Experimental; Melphalan; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neovascularization, Pathologic; Xanthenes; Xanthones | 1997 |
Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Hypoxia; Fibrosarcoma; Humans; Mammary Neoplasms, Experimental; Melanoma; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms, Experimental; Organotechnetium Compounds; Oximes; Radionuclide Imaging; Radiopharmaceuticals; Stilbenes; Xanthenes; Xanthones | 2000 |
Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Sarcoma, Experimental; Xanthenes; Xanthones | 2001 |
Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Flavonoids; Mammary Neoplasms, Experimental; Nitric Oxide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Xanthenes; Xanthones | 1992 |